safety and efficacy of mirabegron add on treatment to solifenacin in incontinent OAB subjects with an inadequate respose to intial 4 week solifenacin monotherapy

---

drake m., athanasiou s., herholdt c., kaper m., saleem t., huang m., ...Daha Fazla

Annual Meeting of the International-Continence-Society, 6 - 08 Ekim 2015, (Tam Metin Bildiri)

• Yayın Türü: Bildiri / Tam Metin Bildiri
• Dokuz Eylül Üniversitesi Adresli: Evet